Peptides for sexual function

PT-141, the research name for bremelanotide, is the rare peptide in this category with an approved human medicine and phase 3 evidence. The approval is narrow: acquired, generalised hypoactive sexual desire disorder in premenopausal women in the United States. It is not an all-purpose libido drug, is not approved for men or postmenopausal women, and is not a general treatment for erectile dysfunction. The evidence is real, but it answers a smaller question than most online claims suggest.

Desire and erection are different outcomes

Sexual function is an umbrella term. Desire, arousal, erection, lubrication, orgasm, pain and relationship distress are separate outcomes with different causes. Bremelanotide activates melanocortin receptors in the central nervous system rather than directly widening penile blood vessels like a PDE5 inhibitor. The Vyleesi label states that the mechanism by which it improves hypoactive sexual desire disorder is unknown^[1]. That uncertainty is not unusual, but it limits simple claims about what the drug is supposed to fix.

The approved indication has several boundaries. The label covers premenopausal women with low desire that developed after a period of normal function, occurs across situations and partners, causes marked distress, and is not explained by a medical or psychiatric condition, relationship problem, or medication effect. It explicitly excludes postmenopausal women and men and says the medicine is not indicated to enhance sexual performance^[1]. Those exclusions should be read before any efficacy number.

What the phase 3 trials found

The pivotal RECONNECT programme consisted of two randomised, double-blind, placebo-controlled phase 3 trials. They enrolled 1,267 premenopausal women, with 1,202 included in the efficacy analysis, and compared subcutaneous bremelanotide with placebo over 24 weeks. Both studies found statistically significant improvement in the Female Sexual Function Index desire score and reduced distress related to low desire^[2]. The drug did not significantly increase the number of satisfying sexual events, a co-primary endpoint used earlier in development^[2].

That combination is more informative than a single headline. Some participants reported more desire and less distress, but the trials did not show a clear rise in event count. The result can still matter to a patient whose diagnosed problem is distressing low desire. It does not establish better sexual function for every person, and it does not tell us whether the same balance applies outside the studied population.

The male erectile-dysfunction record is older

PT-141 was also tested in men before the injectable product was approved for women. A double-blind, placebo-controlled intranasal study included healthy men and men with mild to moderate erectile dysfunction who responded to sildenafil. Doses above 7 mg produced a statistically significant erectile response measured by RigiScan, with the first erection beginning at about 30 minutes. Flushing and nausea were the most common adverse events^[3]. This was an experimental nasal formulation, not the approved injection.

Another randomised crossover study gave 19 men a low intranasal amount of PT-141 with 25 mg sildenafil, sildenafil with placebo spray, or double placebo. The combination produced a greater laboratory-measured erectile response than sildenafil alone during visual sexual stimulation^[4]. A later trial in 342 men who reported not responding to sildenafil found more positive clinical results with intranasal bremelanotide than placebo, but also more drug-related adverse effects^[5]. None of these trials produced a current approval for erectile dysfunction.

Safety is part of the result

In the approved programme, nausea was the most common adverse effect. The label reports nausea in 40 percent of treated patients versus 1.3 percent with placebo, flushing in 20.3 percent versus 0.3 percent, and headache in 11.3 percent versus 1.9 percent^[1]. Bremelanotide can temporarily raise blood pressure and lower heart rate after each dose. Uncontrolled hypertension and known cardiovascular disease are contraindications^[1]. The label also warns about focal hyperpigmentation, including changes to the face, gums and breasts, which may not resolve after stopping^[1].

These findings are why a prescription context matters. A clinician can screen for cardiovascular risk, review other medicines and investigate causes of low desire or erectile difficulty that require a different treatment. A vial marketed online as PT-141 is not the regulator-reviewed Vyleesi autoinjector. The PT-141 regulatory overview explains the approval and access split.

What we don't yet know

The phase 3 record does not tell us how well injectable bremelanotide works for postmenopausal women, men, people whose low desire is caused by another condition, or people seeking performance enhancement. The older male trials used an intranasal formulation and often laboratory stimulation or combination treatment. We do not have a completed modern phase 3 programme establishing benefit and safety for male erectile dysfunction. We also lack good evidence for the fixed daily or very-low-dose schedules discussed in peptide forums.

Where this leaves a reader

Bremelanotide has better evidence than most compounds sold as peptides for sexual function. That does not make every use evidence-based. The fair reading is one approved use in a carefully defined group, plus older experimental findings in men that did not become an approval. If low desire, erection difficulty, pain or another sexual problem persists, a clinician can separate those issues and look for hormonal, cardiovascular, medication-related and psychological causes. For jurisdiction-specific information, see the United States PT-141 page and the United Kingdom PT-141 page.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.